Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders

Rhea-AI Summary

Resverlogix Corp. (TSX: RVX, OTC: RVXCF) held its Annual Meeting of Shareholders on June 30, 2025, in Calgary, Alberta. During the meeting, shareholders elected four Board members with strong approval rates ranging from 96.55% to 97.11%.

The elected Board members include Donald J. McCaffrey (96.55% approval), Kelly McNeill (96.79% approval), Siu Lun To (97.11% approval), and Kenneth Zuerblis (96.94% approval). All resolutions outlined in the May 16, 2025 Notice of Meeting and Management Information Circular were approved by shareholders.

Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta.

During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:

	Votes For	Votes Withheld	Percent For	Percent Withheld
Donald J. McCaffrey	144,544,411	5,161,746	96.55%	3.45%
Kelly McNeill	144,898,132	4,808,025	96.79%	3.21%
Siu Lun (Dicky) To	145,379,921	4,326,236	97.11%	2.89%
Kenneth Zuerblis	145,121,418	4,584,739	96.94%	3.06%

 

Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 16, 2025 (the "Information Circular"). The Information Circular is available on SEDAR+ at www.sedarplus.ca, and on the Resverlogix website at www.resverlogix.com.

A webcast archive of the executive presentation portion of the Meeting will be available HERE.

About Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions — altered by serious illnesses such as cardiovascular disease — back to a healthier state.

The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Follow us on:

• Twitter: @Resverlogix_RVX
• LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/

Forward-Looking Statements:

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

www.resverlogix.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257377

FAQ

Who are the newly elected Board members of Resverlogix (RVXCF) for 2025?

The four elected Board members are Donald J. McCaffrey, Kelly McNeill, Siu Lun (Dicky) To, and Kenneth Zuerblis.

What was the highest approval rating received by a Resverlogix Board member in the 2025 election?

Siu Lun (Dicky) To received the highest approval rating of 97.11% with 145,379,921 votes in favor.

Where can investors find Resverlogix's 2025 Management Information Circular?

The Information Circular is available on SEDAR+ at www.sedarplus.ca and on the Resverlogix website at www.resverlogix.com.

What was the date of Resverlogix's 2025 Annual Meeting of Shareholders?

Resverlogix held its Annual Meeting of Shareholders on June 30, 2025 in Calgary, Alberta.